期刊文献+

HPLC测定人血浆中的10α-甲氧基-6-甲基麦角林-8β-甲醇 被引量:2

Determination of 10α-methoxy-6-methylergoline-8β-methanol in human plasma by HPLC
原文传递
导出
摘要 目的采用HPLC测定人血浆中尼麦角林主要代谢物10α-甲氧基-6-甲基麦角林-8β-甲醇(MDL)的血药浓度。方法色谱柱为Luna C18柱(250 mm×4.6 mm,10μm),流动相为乙腈-0.01 mol·L^-1磷酸氢二钠(15:85,磷酸调pH3.5),流速为1.0 ml·min^-1,柱温30℃,检测波长为225 nm。结果线性范围为5.0~80.0 ng·ml^-1(r=0.9997,n=7),平均方法回收率分别为93.85%、94.83%、89.84%;日内RSD分别为4.93%、8.23%、10.63%(n=5),日间RSD分别为6.17%、6.13%、8.41%(n=5)。结论该法灵敏、简便、准确,适用于尼麦角林及相关制剂的临床研究。 OBJECTIVE To establish the method for determination of 10α - methoxy - 6 - methylergoline - 8β - methanol ( MDL, a main metabolite of Nicergoline) in human plasma by HPLC. METHODS Chromatographic column was based on Luna C18 (250 mm × 4.6 mm, 10 μm). The mobile phase consisted of acetonitrile: 0.01 mol·L^-1 disodium hydrogen phosphate (15 : 85, pH3.5 )with a flow rate of 1.0 ml·min^-1. The column temperature was 30℃. The detecting wavelength was 225 nm. RESULT The linear range was 5.0 - 80.0 ng·ml^ -1 ( r = 0. 9997, n = 7 ). The average method recovery were 93.85% ,94.83% and 89.84 %. The intra - day RSD were 4.93 %, 8.23 % and 10.63 % ( n = 5 ), and the inter - day RSD were 6.17% ,6.13 % and 8.41% ( n = 5 ). CONCLUSION The method was sensitive, simple, and reliable, and suitable for determination of nicergoline and other correlated dose forms of nicergoline on clinical study.
出处 《华西药学杂志》 CAS CSCD 北大核心 2009年第5期519-520,共2页 West China Journal of Pharmaceutical Sciences
关键词 高效液相色谱法 尼麦角林 10a-甲氧基-6-甲基麦角林-8β-甲醇(MDL) 血药浓度 代谢物 HPLC Nicergoline 10α - methoxy- 9,10 - dihydrolysergol ( MDL ) Plasma - drug concentration Metabolite
  • 相关文献

参考文献4

二级参考文献19

  • 1魏秋玻.尼麦角林联合胞二磷胆碱治疗血管性痴呆的临床研究[J].药学进展,2004,28(9):421-424. 被引量:2
  • 2张晓景.尼麦角林的药理作用及临床应用[J].西北药学杂志,2006,21(6):286-287. 被引量:23
  • 3王梅平,林锦镛,宋丽英.脑通对增进缺血性脑血管病血供的TCD观察[J].海峡药学,1996,8(2):26-27. 被引量:1
  • 4仇丽颖,张丹.尼麦角林在大鼠体内的药代动力学研究[J].药物分析杂志,2007,27(3):328-331. 被引量:3
  • 5Alvarez-Guerra M,Bertholom N,Garay RP.Elective blockade by nicergoline of vascular responses elicited by stimulation of alpha I A-adrenoceptor subtype in the rat[J].Fundam Clin Pharmacol,1999,13(1):1-4.
  • 6Benzi G,De Bernardi M,Manzol L,et al.Effect of lysergide and nicergoline on glucose metabolism investigated on the dog brain isolated in situ[J].J Pharm Sci,1972,61:348-352.
  • 7Carfagna N,Di-Clemente A,Cavanus S,et al.Odulation of hippocampal Ach release by chronic nicergoline treatment in freely moving young and aged rats[J].Neurosci Lett,1995,3:195-198.
  • 8Davis RE,Emmerling MR,Jaen JC,et al.Therapeutic intervention in dementia[J].Crit Rev Neurobiol,1993,7:41-83.
  • 9Carfagna N,Cavanus S,Damiani D,et al.Modulation of phosphoinositide turnover by chronic nicergoline in rat brain[J].NeurosciLett,1996,3:189-192.
  • 10Chandra P,Paul A.The effect of nicergoline and other vasoactive substances on molecular biological processes in the brain and their effect on the learning abilities of rats.In:Heidrich H,ed.proof of therapeutical effectiveness of nootropic and vasoactive drufs[J].Berlin,Springer Verlag,1985:119-130.

共引文献27

同被引文献9

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部